Corona vaccine: China started using covid vaccine out of trial in July

A senior Chinese health official has said that the Chinese government has been providing the Corona vaccine to those working in select areas since July, which have not yet been fully approved.

Cheng Chongyi, head of the National Health Commission's Center for Science and Technology, told the CCTV, a government media body, that the government had approved the vaccination of SARS-COVID-2 (ie COVID-19) to health workers and officials on the border for 'emergency use' Was allowed to give

Cheng is leading the task force developing the vaccine.

He said that no new cases of localized infection have been reported in China since seven days.

Those who work at the border are believed to be at greater risk.

This is the first case of vaccine use outside clinical trials in China that has been confirmed.

There is no complete information about which vaccines were given to these people and how many were given to them, but Cheng says that this was done completely by following the law under which the non- Limited use of certified vaccines is permitted.

"We have prepared a whole series of plans, including a medical consent, side effect monitoring plan, rescue plan and compensation plan to ensure that this emergency is fully utilized," Cheng told CCTV. Is organized and monitored.

He informed that it is also planned to test it on other groups before autumn and winter.

The World Health Organization is monitoring the ongoing work on 170 potential vaccines worldwide.

Many vaccines in China have reached the Phase III trial. In this phase, thousands of people will be tested to be safe and effective by giving the vaccine.

In June, the Chinese government asked those working in government companies to become volunteers to test two vaccines. These are the employees who always have to travel to other countries.

State-run China National Biotech Group has received approval to test its vaccine on humans in the United Arab Emirates, Bahrain, Peru, Morocco and Argentina.

The company has reported that 20,000 people are participating in trials in these countries outside.

Other Chinese companies Sinovac and Cancino Biologics are also conducting trials in Russia, Indonesia and Brazil.